University of Ioannina
Εκτίμηση της αποτελεσματικότητας, της ασφάλειας και της επίδρασης του συνδυασμού φαρμάκων στις μεταβολικές παραμέτρους του ορού υπέρβαρων και παχύσαρκων ασθενών με υπερχοληστερολαιμία
Abstract
dc:descriptionThe purpose of the present study was to evaluate the safety and effects of orlistat and ezetimibe, alone or in combination, on anthropometric and metabolic parameters, LDL and HDL subclasses as well as on enzyme activities associated with atherosclerosis in overweight and obese patients with hypercholesterolemia. Ninety-four subjects with BMI > 28 kg/m2 and total cholesterol levels > 200 mg/dL (5.2 mmol/L) were prescribed a low-fat, low-calorie diet and were randomly allocated to receive orlistat 120 mg, 3 times daily (O group), ezetimibe 10 mg/day (E group) or both (OE group) for 6 months. Τhe reductions in LDL-C and sdLDL-C was significantly greater in the OE group (- 32% and -76%, respectively) compared with the O (-19% and -45%, respectively) and E groups (-21% and -48%, respectively), (p < 0.05 for all comparisons). The reduction in sdLDL-C levels correlated significantly with TG reduction in all treatment groups. Body mass index (BMI), waist circumference, and body weight reductions were significantly greater in groups O and OE compared with group E (p < 0.05 for all comparisons). The reduction in Lp-PLA2 activity was significantly greater in OE group compared with O and E groups (p < 0.05 for all comparisons). In group O the cholesterol concentration of HDL2 subclass increased significantly (p < 0.05), while the cholesterol of HDL3 subclass decreased significantly (p < 0.05). In groups E and OE HDL2 levels did not change significantly, while the cholesterol concentration of HDL3 subclass decreased significantly (p < 0.05). The PON1(phenylacetate)/LDL-C ratio increased significantly more in the OE group compared with the O and E groups (p < 0.05 for all comparisons). Furthermore, HDL-Lp-PLA2/LDL-C ratio increased significantly more in the OE compared with E group (p < 0.05). The reduction in apoC-III levels was significantly greater in OE group compared with O group (p < 0.05). The reduction in apoC-II levels in E and OE groups was significantly greater compared with O group (p < 0.05 for all comparisons). In OE group alterations in apoC-III levels were independently and significantly positively correlated with TG lowering. In conclusion, orlistat plus ezetimibe combination appears to be safe and has a more favorable effect on metabolic and lipid parameters, as well as on LDL particle distribution and enzyme activities associated with atherosclerosis than either drug alone in overweight and obese patients with hypercholesterolemia.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2012
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Nakou, Eleni
- Νάκου, Ελένη
Subjects
dc:subject × 20- Παχυσαρκία
- Ορλιστάτη
- Εζετιμίμπη
- Υπερχοληστερολαιμία
- Φωσφολιπάση Α2, Συνδεδεμένη με τις λιποπρωτεΐνες
- Απολιποπρωτεΐνες C - II και C - III
- Παραοξονάση 1
- Υποκλάσματα των χαμηλής και υψηλής πυκνότητας λιποπρωτείνων
- Obesity
- Orlistat
- Ezetimibe
- Hypercholesterolemia
- Lipoprotein-associated phospholipase A2
- Apolipoproteins C-II AND C-III
- Paraoxonase 1
- Subclasses of high and low density lipoproteins
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/28241